17 results about "Lysophosphatidylcholine" patented technology

The present application relates to the technical field of feed additive, and discloses a lactation-promoting functional feed for lactating sows containing high-efficiency plant lactogenic factors, which is made of the following raw materials: sodium-based montmorillonite, fenugreek extract, motherwort extract, ion intensity regulator, lysophosphatidylcholine, tributyl citrate and high-purity silicon dioxide, and is prepared through the following steps: mixing and drying sodium-based montmorillonite with the ion intensity regulator to prepare a regulation carrier; adding fenugreek and motherwort extract and mixing them by strong shearing to form an active core; atomizing and spraying a mixture of lysophosphatidylcholine and tributyl citrate on the surface of the core to form a functional layer; and finally adding high-purity silicon dioxide and mixing uniformly to obtain the feed. Through the construction of the structure with ion-pretreated montmorillonite as the core and the functional layer as the shell, the present application realizes the protection, sustained release and efficient absorption of the active ingredients, and improves the bioavailability.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for evaluating the prognosis of patients with hypertrophic cardiomyopathy and application thereof. The application determines that one or more of 3-hydroxyrilotene, asparagine-lysine, cyclohexylamine, arachidonic acid, aconitic acid, propionyl carnitine, ceramide, tryptophan, 3-hydroxysebacic acid, traumatic acid, phosphatidylcholine, alanine-proline, lysophosphatidylcholine, taurine and S-garlicin cysteine are related to the prognosis of hypertrophic cardiomyopathy, can evaluate the prognosis of patients with hypertrophic cardiomyopathy after undergoing muscle resection of interventricular septum, and shows accurate judgment on all-cause death or rehospitalization, cardiovascular events and postoperative new-onset arrhythmia. Finally, all the prognostic biomarkers are reproduced in an independent cohort, which is helpful for postoperative risk evaluation of patients with hypertrophic cardiomyopathy, has high specificity and high sensitivity.

The invention relates to the non-therapeutical use of phosphatidylcholine and / or lyso- phosphatidylcholine for increasing the nutrient retention of at least one Long-Chain Fatty Acid (LCFA) in an animal or a human, or to a use of phosphatidylcholine and / or lyso- phosphatidylcholine for increasing the thermal stability of at least one Long-Chain 5 Unsaturated Fatty Acid (LC-UFA). The invention further relates to an ingestible composition, and a method of preparation of such a composition.

This invention provides an application and method of lysophosphatidylcholine (LPC) in promoting early development of reconstructed embryos, belonging to the field of embryo engineering technology. The invention first prepares reconstructed embryos, then adds lysophosphatidylcholine to the culture system for culturing. Lysophosphatidylcholine effectively promotes early development of the reconstructed embryos; at an optimal concentration of 5 μM, the blastocyst development rate increases to 24.56%, providing a novel and operable biochemical intervention target to solve the problem of low reconstructed embryo culture efficiency. This invention not only fills the gap in our understanding of the mechanism of action of LPC in this field, but also achieves controllability and reproducibility of the technical solution through precise definition of the optimal concentration. It provides key parameters for establishing standardized culture procedures and provides a more solid foundation for downstream applications such as developmental biology research and disease model construction that rely on high-quality reconstructed embryos, significantly accelerating the process of related scientific discovery and application development.

The invention relates to an emulsifying agent characterized in that it comprises 5% to 30% by weight of lysophosphatidylcholine (LPC)-enriched phospholipids in a suitable vehicle. The invention also relates to the use of this emulsifying agent in the preparation of topical compositions, particularly cosmetics, and to said compositions themselves.

The application discloses a phospholipase A1 mutant and application thereof. In the application, the PLA1 mutant is obtained by modifying the PLA1, wherein compared with the wild-type PLA1, the optimal temperature of the PLA1 mutant remains unchanged, and the PLA1 mutant has higher phospholipase A1 activity between 40-50 DEG C; the optimal pH of the PLA1 mutant is changed from 3 to 8; the PLA1 mutant has high phospholipase activity at pH 3-9, and the phospholipase activity is higher than that of the wild-type PLA1 under the optimal condition; and the pH adaptability range of the PLA1 is widened. Therefore, the PLA1 mutant has better application prospect, and meets the requirement of the enzyme performance in phospholipid processing, and can be applied to oil degumming, production of lysophosphatidylcholine, and application in the fields of biology, food, medicine, beauty, agriculture and industry.

The invention discloses a detection method of lysophosphatidylcholine, which can realize good separation of lysophosphatidylcholine and other components in a preparation sample by optimizing a chromatographic column, adjusting a mobile phase and using isocratic elution, greatly shortens the operation time of a single needle, and improves the detection efficiency.

The present invention relates to a lipid complex for the nasal delivery of nucleic acid molecules comprising ionized lipids, structural lipids, cholesterol, and lysoPC as active ingredients. The lipid complex of the present invention can be usefully utilized for the local and intensive delivery of therapeutic nucleic acid molecules specifically to nasal epithelial cells by efficiently being compatible with the microenvironment unique to nasal tissue, easily penetrating the mucus layer barrier, and effectively escaping endosomes. Furthermore, the lipid complex of the present invention can be applied as a combination administration platform that induces a synergistic therapeutic effect by two pharmacological components by loading additional drugs into internal compartments of the lipid complex, as well as improving dispersibility by loading the target nucleic acid molecule externally.

The application discloses a metabolic marker composition for early cervical cancer diagnosis and a screening method and application thereof. The metabolic marker composition for early cervical cancer diagnosis comprises pyroglutamic acid, lysophosphatidylcholine 20:3, phosphatidylcholine 32:2 and pyruvic acid. The metabolic marker composition provided by the application has high sensitivity and specificity when used for early cervical cancer diagnosis, can realize precise screening of early cervical cancer, and provides important help for prevention of cervical cancer and reduction of morbidity. Meanwhile, the metabolic marker composition is simple in operation, convenient in sample acquisition, low in cost, and non-invasive when used for early cervical cancer diagnosis, so that patients can more conveniently, quickly and safely receive detection, and is more suitable for large-scale population screening and regular tracking in areas with tight medical resources.

The invention provides a metabolic marker combination for thyroid cancer diagnosis or auxiliary diagnosis and application of the metabolic marker combination, and belongs to the technical field of in-vitro diagnosis. According to the invention, phosphatidyl ethanolamine 36: 6e, erucic acid, triglyceride 58: 2, lysophosphatidylcholine 22: 5, cholic acid, L-glutamic acid and L-valyl-L-serine are combined to construct a diagnosis model for distinguishing healthy and benign thyroid diseases and thyroid cancer, and the diagnosis model has high diagnosis efficiency and clinical diagnosis significance. Besides, diagnosis models for distinguishing healthy diseases, thyroid benign diseases and thyroid cancer are respectively constructed for 9 metabolic markers and 11 metabolic markers comprising the metabolic marker combination, and the diagnosis models constructed by the 9 metabolic markers and the 11 metabolic markers are proved to have relatively high diagnosis efficiency; healthy and benign thyroid diseases and thyroid cancer can be effectively distinguished, and clinical diagnosis significance is achieved.

The invention relates to the technical field of skin care products, and discloses a phospholipid complex for preparing a nano-emulsion and a preparation process, the phospholipid complex contains hydrogenated phosphatidylcholine and hydrogenated lysophosphatidylcholine, the ratio of hydrogenated phosphatidylcholine to hydrogenated lysophosphatidylcholine is 200-10: 1, the phospholipid complex is a phospholipid complex, and the phospholipid complex is a phospholipid complex. The nano-emulsion prepared by the invention can be efficiently absorbed in a transdermal manner, the bioavailability of active ingredients is improved, and the product is low in irritation and high in safety.

The invention discloses an application of lysolecithin in preparation of a product for protecting immune stress of pigs, the body health of the pigs in an immune stress scene can be protected by feeding the pigs with the product containing the lysolecithin, and the damage of intestinal tracts and livers of the pigs caused by lipopolysaccharide stimulation can be relieved, so that the immune stress of the pigs can be protected. The purpose of preventing the pig intestinal injury and / or liver injury can be achieved, the purpose of treating the pig intestinal injury and / or liver injury can also be achieved, and the pig intestinal injury and / or liver can be protected.

This invention relates to the field of animal feed technology and discloses a compound nutritional feed suitable for the growth and development of Ili horses in high-altitude and cold regions. The feed comprises 88-92 parts roughage and 8-12 parts solid-dispersed microspheres. The solid-dispersed microspheres are made of hydrogenated palm oil, calcium propionate, anhydrous citric acid, and lysophosphatidylcholine, and have a lipid crystalline network structure. In an aqueous environment, the lysophosphatidylcholine within the microspheres establishes hydration channels, promoting water penetration and triggering an in-situ acid-base metathesis reaction between calcium propionate and anhydrous citric acid. The resulting liquid free propionic acid causes a sharp drop in the local melting point of the microspheres, leading to the disintegration of the macroscopic structure. This invention can simultaneously release free propionic acid and hydrogenated palm oil, providing energy through gluconeogenesis and intestinal enzymatic hydrolysis, respectively, achieving a dual-effect synergistic energy supply from carbohydrates and lipids. This meets the energy metabolism needs of Ili horses in high-altitude and cold environments and exhibits good long-term storage stability.

The method for improving the extreme acid stress tolerance of Lactobacillus kefiranofaciens disclosed by the scheme belongs to the technical field of microorganisms and comprises the following steps: step one, strain activation: adding glycerophosphocholine into a modified MRS culture medium, then inoculating Lactobacillus kefiranofaciens for activation culture to obtain an activated bacterial solution; step two, stress adaptation culture: inoculating the activated bacterial solution obtained in step one into a stress adaptation culture medium, performing stress domestication by gradually reducing the pH, and adding lysophosphatidylcholine during the domestication process, and then performing culture to obtain a domesticated bacterial solution; and step three, fermentation system strengthening: inoculating the domesticated bacterial solution obtained in step two into a target fermentation system, and supplementing glycerophosphocholine or its hydrochloride into the fermentation system for fermentation. The method can significantly improve the survival ability and metabolic stability of Lactobacillus kefiranofaciens in an extreme acid environment.

The application provides a lysophosphatidylcholine (LPC) kit with anti-coccidiosis effect, and discloses a diagnosis marker for Eimeria tenella infected chicken, which is characteristic phospholipid and sphingolipid molecules, and specifically phosphatidylcholine (PC), lysophosphatidylcholine (LPC) and sphingomyelin (SM). Meanwhile, the application provides a medicine composition for improving the survival rate of chicks infected with Eimeria tenella, which is characterized by containing effective amounts of 18:2 LPA, 18:1 LPC, 22:0 LPC, 16:0 18:1 PC, 16:0 18:2 PC and d18:1 16:0 SM. The application screens characteristic phospholipid and sphingolipid molecules in the cecum tissue of chicken infected with Eimeria tenella for the first time, and verifies the curative effect of phosphatidylcholine (PC), lysophosphatidylcholine (LPC) and sphingomyelin (SM) on acute infection of chicks with Eimeria tenella, which has great market development prospect.

The invention provides a characteristic phospholipid molecular biomarker in plasma, a screening method thereof and application of the characteristic phospholipid molecular biomarker in preparation of a kit for diagnosing pneumoconiosis. The characteristic phospholipid molecules at least comprise the following nine phospholipid molecules: lysophosphatidylcholine (12: 0), phosphatidylcholine (16: 0 / 16: 0), phosphatidylcholine (18: 0 / 18: 1), phosphoinositide (16: 0 / 18: 1), lysophosphatidic acid (16: 0), phosphatidyl glycerol (16: 0 / 16: 0), phosphatidylserine (18: 1 / 18: 1), phosphatidylcholine (18: 0 / 20: 2) and lysophosphatidyl ethanolamine (18: 2). The TC value is calculated by calculating the quantitative values of the nine characteristic phospholipid molecules and a classification model constructed based on a support vector machine algorithm, the risk of pneumoconiosis is predicted according to the TC value, pneumoconiosis patients and non-pneumoconiosis patient groups can be accurately distinguished, and the method is used for pneumoconiosis diagnosis and early screening.

The invention provides a combined marker combination as well as a detection method and a kit thereof. The combined marker combination comprises a plasma protein marker and a blood metabolism marker, the plasma protein marker comprises an adaptor protein PH-containing structural domain, enolase 3, a proline 4-hydroxylase alpha1 chain and ethanol dehydrogenase 1C, and the adaptor protein comprises an adaptor protein PH-containing structural domain, a proline 4-hydroxylase alpha1 chain and a proline 4-hydroxylase alpha2 chain. The blood metabolism marker is prepared from diosgenin, eicosapentaenoic acid, folinic acid, hydroxyprogesterone hexanoate, testosterone, perfluorooctane sulfonic acid, prasterone sulfate, androstane dienone, long pine needle ketone and 1-(22 carbon 4 enoyl) lysophosphatidylcholine. Through cooperative detection of protein-metabolism markers and combined application of a machine learning model, accurate prediction of the age-related disease risk is achieved, the cognitive decline risk can be pre-judged in advance, meanwhile, efficient synchronous detection of multiple markers is achieved by means of a liquid chromatography-tandem mass spectrometry synchronous detection technology, the sample dosage is small, the detection process is standardized, and the detection efficiency is high. The large-scale queue research requirement is met, and multi-center clinical application and popularization are facilitated.